Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 6
Submit an article Journal homepage
1,317
Views
7
CrossRef citations to date
0
Altmetric
Gastroenterology

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Fernando RiveraHospital Universitario Marqués de Valdecilla, Santander, Spain;
,
Manuel ValladaresHospital Universitario Virgen del Rocío, Sevilla, Spain;
,
Salvador GeaUnidad de Farmacoeconomía e Investigación de Resultados en Salud, AMGEN, S.A., Barcelona, Spain;
&
Noemí López-MartínezOblikue Consulting S.L., Barcelona, SpainCorrespondence[email protected]
Pages 574-584 | Received 26 Sep 2016, Accepted 18 Jan 2017, Published online: 07 Feb 2017

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

María Presa, David Vicente, Antonio Calles, Laura Salinas-Ortega, Jaesh Naik, Luis F García & Javier Soto. (2023) Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. ClinicoEconomics and Outcomes Research 15, pages 659-671.
Read now
Christopher N. Graham, Alexandra Christodoulopoulou, Hediyyih N. Knox, Lorenzo Sabatelli, Guy Hechmati, Tamer Garawin & John H. Strickler. (2018) A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Journal of Medical Economics 21:11, pages 1075-1083.
Read now

Articles from other publishers (5)

Takashi Morimoto, Kaori Fujito, Bumpei Yamasaki & Rei Goto. (2023) Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. Clinical Therapeutics 45:1, pages 41-54.
Crossref
Stavroula Koilakou & Panagiotis Petrou. (2021) Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Molecular Diagnosis & Therapy 25:6, pages 715-734.
Crossref
E. V. Eliseeva, Yu. Yu. Petukhova & A. G. Petukhova. (2020) Cost-effectiveness indicator for colorectal cancer therapy. Pacific Medical Journal:4, pages 24-28.
Crossref
Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs & Maarten IJzerman. (2020) Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. PharmacoEconomics 38:7, pages 683-713.
Crossref
Mikyung Kelly Seo & John Cairns. (2018) Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLOS ONE 13:9, pages e0204496.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.